{"organizations": [], "uuid": "284fc43da4cdda9784ea2fb77da657a7bdfb33df", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-merrimack-says-dosed-first-patient/brief-merrimack-says-dosed-first-patient-in-randomized-phase-2-clinical-study-of-mm-121-idUSFWN1QG0T2", "country": "US", "domain_rank": 408, "title": "BRIEF-Merrimack Says Dosed First Patient In Randomized Phase 2 Clinical Study Of MM-121", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-26T14:20:00.000+02:00", "replies_count": 0, "uuid": "284fc43da4cdda9784ea2fb77da657a7bdfb33df"}, "author": "", "url": "https://www.reuters.com/article/brief-merrimack-says-dosed-first-patient/brief-merrimack-says-dosed-first-patient-in-randomized-phase-2-clinical-study-of-mm-121-idUSFWN1QG0T2", "ord_in_thread": 0, "title": "BRIEF-Merrimack Says Dosed First Patient In Randomized Phase 2 Clinical Study Of MM-121", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters staff", "sentiment": "none"}, {"name": "reuters) - merrimack pharmaceuticals inc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 26, 2018 / 12:22 PM / in 2 minutes BRIEF-Merrimack Says Dosed First Patient In Randomized Phase 2 Clinical Study Of MM-121 Reuters Staff 1 Min Read Feb 26 (Reuters) - Merrimack Pharmaceuticals Inc: * MERRIMACK - ‍ DOSED FIRST PATIENT IN RANDOMIZED PHASE 2 CLINICAL STUDY OF MM-121 IN PATIENTS WITH POST-MENOPAUSAL METASTATIC BREAST CANCER​ * MERRIMACK PHARMA SAYS SHERLOC PHASE 2 STUDY ASSESSING MM-121 WITH DOCETAXEL VERSUS DOCETAXEL ALONE IS EXPECTED TO DELIVER TOP-LINE DATA IN H2 2018 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)", "external_links": [], "published": "2018-02-26T14:20:00.000+02:00", "crawled": "2018-02-26T14:25:55.025+02:00", "highlightTitle": ""}